Results 1 to 10 of about 442,026 (299)
Apollo Medicine, 2004 Advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease.
G. Ossenkoppele
semanticscholar +4 more sources
Genomic Classification and Prognosis in Acute Myeloid Leukemia
New England Journal of Medicine, 2016 Background Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice.
Michael Heuser +2 more
exaly +2 more sources
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
New England Journal of Medicine, 2013 BACKGROUND Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not yet clear.
Ken Chen, John Welch, Aly Karsan
exaly +2 more sources
Advances in acute myeloid leukemia [PDF]
BMJ, 2021 Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
Laura F. Newell, R. Cook
semanticscholar +3 more sources
The proteogenomic subtypes of acute myeloid leukemia
Cancer Cell, 2022 Summary Acute myeloid leukemia (AML) is an aggressive blood cancer with poor prognosis. We report a comprehensive proteogenomic analysis of bone-marrow biopsies from 252 uniformly treated AML patients to elucidate the molecular pathophysiology of AML in ...
Uwe Plessmann +2 more
exaly +2 more sources
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
New England Journal of Medicine, 2017 Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase inhibitor that is active in patients with a FLT3 ...
Clara Bloomfield +2 more
exaly +2 more sources
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
New England Journal of Medicine, 2012 BACKGROUND Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for ...
Rhett Ketterling +2 more
exaly +2 more sources
Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia
Cancer Cell, 2019 Summary FTO, a mRNA N6-methyladenosine (m6A) demethylase, was reported to promote leukemogenesis. Using structure-based rational design, we have developed two promising FTO inhibitors, namely FB23 and FB23-2, which directly bind to FTO and selectively ...
Zhijian Qian, Cai-Guang Yang, Hu Zhou
exaly +2 more sources
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
New England Journal of Medicine, 2009 BACKGROUND The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a
Ken Chen, Jason Walker, David Larson
exaly +2 more sources
Blood, 2022 The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology.
D. Arber +67 more
semanticscholar +1 more source